Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and ongoing challenges within its operations.</li><li>The company achieved an adjusted diluted EPS of $1.62, which exceeded prior expectations.</li><li>This outperformance was partly due to tax benefits projected for later in the year being realized earlier, as well as some accelerated income tax benefits.</li></ul>

Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and ongoing challenges within its operations.The company achieved an adjusted diluted EPS of $1.62, which exceeded prior expectations.This outperformance was partly due to tax benefits projected for later in the year being realized earlier, as well as some accelerated income tax benefits.

Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! - Major Drivers

<ul><li>Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of modified earnings and strategic developments across various business units.</li><li>Notably, the company exceeded their expected adjusted earnings per share (EPS) at $2.26, prompting an upward revision in their full-year 2024 forecast to over $6.80 per share.</li><li>While these results show solid progress and operational efficiency, they frame a nuanced picture—detailing areas of strength alongside ongoing challenges.</li></ul>

Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of modified earnings and strategic developments across various business units.Notably, the company exceeded their expected adjusted earnings per share (EPS) at $2.26, prompting an upward revision in their full-year 2024 forecast to over $6.80 per share.While these results show solid progress and operational efficiency, they frame a nuanced picture—detailing areas of strength alongside ongoing challenges.

Centene Corporation: Medicaid Managed Care Expansion and Optimization! - Major Drivers

<ul><li>Centene Corporation reported its first quarter 2024 results, highlighting several positive developments and strategic maneuvers aimed at sustaining and enhancing its business operations.</li><li>The company achieved a higher-than-expected adjusted EPS of $2.26, prompting an upward revision in its full-year 2024 EPS guidance to over $6.80.</li><li>This performance signals a robust start to the year, attributed partly to significant operational improvements and strategic realignments.</li></ul>

Centene Corporation reported its first quarter 2024 results, highlighting several positive developments and strategic maneuvers aimed at sustaining and enhancing its business operations.The company achieved a higher-than-expected adjusted EPS of $2.26, prompting an upward revision in its full-year 2024 EPS guidance to over $6.80.This performance signals a robust start to the year, attributed partly to significant operational improvements and strategic realignments.

Centene Corporation: Leveraging Dual Eligibles in Medicare and Medicaid & Other Major Drivers

<ul><li>Centene Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.</li><li>For the quarter, they increased their expectation for 2023 premium and service revenue by an additional $1.8 billion.</li><li>The commercial HBR met the company's expectations, considering the quarter's 200,000 new members and the marketplace's ongoing robust growth.</li></ul>

Centene Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.For the quarter, they increased their expectation for 2023 premium and service revenue by an additional $1.8 billion.The commercial HBR met the company's expectations, considering the quarter's 200,000 new members and the marketplace's ongoing robust growth.

Centene Corporation: Does It Have A Sustainable Competitive Advantage? - Key Drivers

Equity Capital Markets

<ul><li>Centene had a successful first quarter, showing continued positive momentum operationally which was demonstrated by its all-around beat.</li><li>The company raised its premium and service revenue forecast by $3.7 billion, with full-year 2023 adjusted EPS guidance at $6.40.</li><li>We give Centene Corporation a 'Buy' rating with a revised target price.</li></ul>

Centene had a successful first quarter, showing continued positive momentum operationally which was demonstrated by its all-around beat.The company raised its premium and service revenue forecast by $3.7 billion, with full-year 2023 adjusted EPS guidance at $6.40.We give Centene Corporation a 'Buy' rating with a revised target price.

Centene Corporation: Improving Market Position In Medicare Advantage – Key Drivers

United States

Centene Corporation provides multi-line healthcare solutions to individuals across all states and internationally. Centene's specialty services include medicaid and medicare health plans, treatment compliance, and nurse triage.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Centene (CNC UN)

Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! - Major Drivers

Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and...

Baptista Research

Centene Corporation: Medicaid Managed Care Expansion and Optimization! - Major Drivers

Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of...

Baptista Research

Centene Corporation: Leveraging Dual Eligibles in Medicare and Medicaid & Other Major Drivers

Centene Corporation reported its first quarter 2024 results, highlighting several positive developments and strategic maneuvers aimed at...

Baptista Research

Centene Corporation: Does It Have A Sustainable Competitive Advantage? - Key Drivers

Centene Corporation managed to exceed analyst expectations in terms of revenue as well as earnings. For the quarter, they increased their...

Baptista Research

Centene Corporation: Improving Market Position In Medicare Advantage – Key Drivers

Centene had a successful first quarter, showing continued positive momentum operationally which was demonstrated by its all-around beat. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)